488713-29-7 Usage
General Description
3-Chloro-2-iodo-5-nitropyridine is a chemical compound with the molecular formula C5H2ClIN2O2. It is a nitropyridine derivative that contains chlorine, iodine, and nitro functional groups. 3-chloro-2-iodo-5-nitropyridine is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. Its structure and reactivity make it a valuable building block for the production of various organic molecules. Due to its specific chemical properties, 3-chloro-2-iodo-5-nitropyridine is an important compound in the field of organic chemistry and has a wide range of applications in research and industrial processes.
Check Digit Verification of cas no
The CAS Registry Mumber 488713-29-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,8,8,7,1 and 3 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 488713-29:
(8*4)+(7*8)+(6*8)+(5*7)+(4*1)+(3*3)+(2*2)+(1*9)=197
197 % 10 = 7
So 488713-29-7 is a valid CAS Registry Number.
488713-29-7Relevant articles and documents
HETEROCYCLIC COMPOUND
-
Paragraph 1066, (2016/03/18)
The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): wherein Ar is a the partial structure (1) to the partial structure (5), Q is a bivalent group selected from the group consisting of (Ia)-(If), and B is a ring optinally having substituent(s), or a salt thereof.
2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS
-
Page 66-67, (2008/06/13)
The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
